Food and Drug Administration - International Pharmaceutical Industry

News

AZ announces US fast track designation for IL-5 inhibitor Fasenra

AstraZeneca’s IL-5 inhibitor Fasenra (benralizumab) has received a fast-track designation from the US Food and Drug Administration for the treatment of eosinoph...

9 November 2021 News AstraZeneca | benralizumab

Continue Reading →

News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...

13 October 2021 News antibody | AstraZeneca

Continue Reading →

News

FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer

The US Food and Drug Administration (FDA) has approved Exelixis’ Cabometyx (cabozantinib) for the treatment of patients with previously treated radioactive iodine-re...

22 September 2021 News Cabometyx | cabozantinib

Continue Reading →

News

FDA approval for Xywav for idiopathic hypersomnia in adults

Jazz Pharmaceutical’s Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults has been granted...

13 August 2021 News FDA | Food and Drug Administration

Continue Reading →

News

FDA approves Keytruda plus Lenvima for advanced kidney cancer

The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the fi...

13 August 2021 News FDA | Food and Drug Administration

Continue Reading →

News

US rejects AZ and FibroGen’s anaemia drug roxadustat

The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat. AZ had submitted a new dru...

13 August 2021 News anaemia drug | AstraZeneca

Continue Reading →